Point72 DIFC Ltd Buys Shares of 65,925 Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Point72 DIFC Ltd purchased a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the third quarter, Holdings Channel.com reports. The fund purchased 65,925 shares of the biopharmaceutical company’s stock, valued at approximately $704,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. M&G Plc grew its position in Amicus Therapeutics by 12.4% in the second quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company’s stock valued at $7,485,000 after acquiring an additional 82,728 shares during the last quarter. Diversified Trust Co boosted its stake in shares of Amicus Therapeutics by 7.8% in the 2nd quarter. Diversified Trust Co now owns 71,803 shares of the biopharmaceutical company’s stock valued at $712,000 after purchasing an additional 5,170 shares in the last quarter. Wedge Capital Management L L P NC grew its holdings in shares of Amicus Therapeutics by 12.3% during the 2nd quarter. Wedge Capital Management L L P NC now owns 233,049 shares of the biopharmaceutical company’s stock valued at $2,312,000 after purchasing an additional 25,564 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in Amicus Therapeutics during the 2nd quarter worth approximately $8,386,000. Finally, AlphaCentric Advisors LLC lifted its stake in Amicus Therapeutics by 15.7% in the 2nd quarter. AlphaCentric Advisors LLC now owns 202,500 shares of the biopharmaceutical company’s stock valued at $2,009,000 after purchasing an additional 27,500 shares during the last quarter.

Wall Street Analyst Weigh In

FOLD has been the subject of several research analyst reports. Jefferies Financial Group assumed coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 price target for the company. Guggenheim upped their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Morgan Stanley dropped their target price on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Finally, Bank of America lifted their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Amicus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.63.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $8,884,273.08. This trade represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold 30,401 shares of company stock valued at $339,363 over the last quarter. Insiders own 2.20% of the company’s stock.

Amicus Therapeutics Price Performance

Amicus Therapeutics stock opened at $9.76 on Friday. The stock’s 50 day moving average is $10.61 and its 200 day moving average is $10.60. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57. The firm has a market cap of $2.92 billion, a P/E ratio of -28.71 and a beta of 0.60.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.